Treatment of immune deficiency and treatment of diseases of the gastrointestinal tract of piglets suckling period

 

(57) Abstract:

The invention relates to veterinary medicine and can be used to enhance the protective immune mechanisms of the body piglets in diseases of the gastrointestinal tract. The method consists in the fact that, along with antibiotics to pigs suckling period intramuscularly administered antihistamine the serum titer of antibodies to histamine is not lower than 1:256 in the dose of 1.5-2.0 ml on the head once a day, three times with an interval of 3-4 days. The method improves the efficiency of correction of immunodeficiency and treatment of diseases of the gastrointestinal tract of piglets suckling period. 3 table.

The invention relates to veterinary medicine, in particular to methods for increasing protective immunological mechanisms of the body of animals with diseases of the gastrointestinal tract, non-infectious etiology.

Currently there are many methods of treatment and prevention of immunodeficiency piglets, increasing their resistance to gastro-intestinal and other diseases in the early period of postnatal development of animals.

There is a method of treatment and prevention of immunodeficiency newborn piglets, when nekotoroi animals as a concentrated serum of pigs (CSC). According to the author (1), it is administered orally, which allows to provide local drug effect on the microflora of the gastrointestinal tract and systemic protection increasing the factors of specific and non-specific resistance of the organism of animals, which contributes to the increase of the piglets by 20%.

The disadvantage of this is similar to the complexity of the technology CSC, which requires special freezer with the programmed cooling rate, which is not always and everywhere available. Moreover, oral administration of the drug (oral application) from a syringe-machine several times a day for 5-6 days, which in large pig farms, with a large number of animals, is almost impossible due to the lack of tools and support personnel.

Known methods of stimulation of protective forces of an organism of pigs in some diseases of the gastrointestinal tract of various etiologies, with the use of drugs such as allogeneic immune serum of pigs (2) and heterogeneous (tarirovannoj) horse blood (3, 4), nonspecific gammaglobulin (8).

Techno slaughtered animals. AISS parenteral stimulates immunobiochemistry reactivity of the organism and the total resistance, but does not provide local protection of the intestines from conditionally pathogenic and pathogenic microorganisms and products of their metabolism. Moreover, the biological activity of this drug depends on the presence of specific antibodies against specific microflora farm, and applying it to other farms, including in the private sector, does not bring the desired success.

Heterogeneous, tsitirovaniya blood horses, contains more total protein, gamma globulin and hemoglobin than the body of pigs, as well as more active biological stimuli than allogeneic blood. This parenteral preparation is used alone, but more often in combination with antibacterial agents. The disadvantage of this method is the exact observance of doses and schemes of use, as may be allergic effect, in the form of anaphylactic shock, stress, which is highly undesirable.

There is a huge variety of ways of treatment of gastrointestinal diseases in animals, characterized by immunodeficiency. The most frequently encountered in the literature schema narushenie technology and feeding, the increase of reactivity, the use of causal antibacterial drugs, money, pathogenetic, substitution and symptomatic therapy.

The closest to the technical nature of the claimed invention is selected as a prototype integrated symptomatic treatment of gastro-intestinal diseases of pigs with simultaneous correction of immune deficiency (4, 8). This method includes the introduction:

- to stimulate the immune system of a mixture of citrate blood horses, nonspecific gammaglobulin, terravita;

- to suppress conditionally pathogenic microflora of the intestinal tract of the antibiotic neomycin sulfate. The sensitivity of microflora to it determined by laboratory studies;

- to maintain the cardiovascular system is applied camphor oil;

- ascorbic acid (Vit. (C) for stimulation of the nonspecific defense factors of the body and as desensitization and antihistamines.

The disadvantage of the prototype is, as practice shows, the material costs for a number of medicinal substances. The doctor should fear velikih drugs. In addition, the introduction of a large number of medicines to animals, increases handling stress and allergization of an organism, as in many animals, there is increased sensitivity to repeated introduction of alien proteins, which is highly undesirable.

Negative aspects of conventional therapy for gastro-intestinal diseases of pigs necessitated the exploration of pathogenetic treatment and effective medicines with immunocorrective properties.

The aim of the invention is to improve the efficiency and simplify the method of treatment of diseases of the gastrointestinal tract of piglets suckling period and the correction of immunodeficiency States. To achieve this goal the piglets at the age of 2-3 weeks with symptoms of diarrhoea and catarrhal gastroenterocolitis along with antibiotic therapy, intramuscularly antihistamine serum (8) in an amount of 1.5-2.0 ml per head, once a day, three times with an interval of 3-4 days.

Comparative analysis of the claimed and known, selected as a prototype methods, allows to identify the features that distinguish the proposed technical Paris 1:256;

diagram introduction AGS: once per day, three times with an interval of 3-4 days.

Analysis of the known technical solutions are not found, the ones that contain similar with the claimed solution of the signs.

Antihistamines serum (AGS) is a liquid straw yellow colour, and contains antibodies against histamine. In addition, the serum contains a number of other biological components, among which the importance of gammaglobulin, ceruloplasmin, lysozyme and antibodies against gistaglobulina with titre not less than 1:256. This drug is produced by hyperimmunization horses gistoglobulina according to a certain scheme.

Selection as a means of treatment of AGS with high titres of antibodies against histamine helps to neutralize the excess of one of the major inflammatory mediators - histamine in animals with gastrointestinal diseases. Increased release of biologically active substances, including histamine, occurs primarily in the intestines, due to the development of degenerative-necrotic and inflammatory processes in the intestinal mucosa after exposure to different damaging agents, including pathogenic bacteria oncemore, reduces the barrier and selective function causes a sudden spastic contractions of the intestinal wall, which further upsets the digestive processes. The accumulation of large amounts of histamine in the body of the sick pigs is due to the decrease in their activity histaminase, failure histaminergic mechanisms, resulting in more broken metabolism, resulting in lower natural resistance of the organism and the development of immunodeficiency.

The authors propose to introduce pigs AGS intramuscularly at a dose of 1.5-2.0 ml per head, once a day, three times with an interval of 3-4 days. Dosage, therapeutic course of treatment with a drug and the antibody titer was developed experimentally. Experiments in healthy piglets early postnatal period showed that the use of AGS in the dose of 1.5-2.0 ml, contributes to a more pronounced activation of hematopoiesis and leucopoiesis, as well as stimulation of the immunological mechanisms of protection of animals due to the additional introduction of serum, it contains lysozyme, immunoglobulins, anti-bacterial antibodies and other biologically active components.

The proposed set of features, Harney therapy piglets with gastrointestinal diseases. This, ultimately, as shown by the study authors, provides high efficiency of treatment of piglets with this disease, reduces recovery time, helps to keep high safety and increase increase in live weight of the animals.

Each of these characteristics is necessary, and all together (in conjunction with other features of the proposed solution) and sufficient to achieve the goal, that is significant.

The presence of significant distinctive features of the prototype characteristics ensures compliance of the inventive combination the criterion of "novelty".

For the implementation of the proposed method was tested in an industrial pig farm LLP Kazanowski" Varna district, Chelyabinsk region to study the effects of serum on the recovery of piglets suffering from dyspepsia and catarrhal gastroenterocolitis noninfectious etiologies, against the background of significant secondary immunodeficiency.

The experiment was conducted on 16 piglets suffering from diarrhoea and catarrhal gastroenterocolitis, body weight 3.5-4.0 kg, 2-3 weeks of age and divided into 2 groups of 8 animals each. In examining the impact of AGS on the stability organizationsee data results histopathology and bacterial studies. Blood tests in patients with animals on such factors as the content of leukocytes and phagocytic activity, the number of b-lymphocytes, T-lymphocytes and their subpopulations: T-helpers and T-suppressors, as well as the level of immunoglobulins, the concentration of histamine, lysozyme and BASK, was performed before treatment and after recovery. Additionally was taken blood from 16 healthy piglets of the same age.

The first group of patients pigs served as control.

She asked:

1. A mixture consisting of nitrate horse blood (1 ml), nonspecific gammaglobulin (1.2 g), terravita (0.5 ml), intramuscularly 1 time a day with an interval of 3 days.

2. Neomycin sulfate orally, 2 times a day, at a dose of 8 thousand UNITS./kg of body weight (soluble in 100 ml of physiological solution).

3. 1 ml of 20% solution of camphor oil 1 times a day for 4 days, subcutaneously.

4. Ascorbic acid (Vit. (C) at a dose of 5 ml of 5% solution/kg body weight 1 time a day for 6 days.

Second, experimental group, received:

1. The antibiotic neomycin sulfate in the same doses as the first;

2. AGS - intramuscularly at a dose of 1.5-2.0 ml per head, once a day is the implementation of appropriate remedial measures all observed indicators in the group of diseased animals was significantly different from those in the group of healthy pigs. It was noted a pronounced imbalance of immune cells and their functional activity, low nonspecific humoral and protective factors and the increased level of free histamine in the blood. After healing all the sick piglets were observed significant differences between experimental and control groups, with a significant advantage of the experimental group before the test.

For example, in the group of piglets treated AGS and antibiotic, the relative amount of T - and b-lymphocytes, T-helper cells, immunoglobulins a and G after recovery was higher, respectively, on 24,5%, 34,1%, 39,9%, 136% and 77.6% of the same parameters of the control group. Simultaneously, the observed marked reduction in the activity of T-suppressor of lymphocyte population 26.8% of circulating immune complexes by 23.0% compared with control. Also was significantly lower than the control level of free histamine. The difference however was 31.1%(P<0,01).

Summarizing the obtained results, we can conclude that the use of antihistamines serum promotes more active stimulation of immune reactivity, increasing the overall resistance of the organism of pigs and normalize the function of the digestive tract. AGS does not cause any toxic or allergenic effects, due to the presence of antibodies against histamine.

Thus, the advantage of the proposed method in comparison with the prototype and other technical solutions can be recommended for use and broad application in veterinary practice antihistamine serum (with antibiotics) for the treatment and prevention of immunodeficiency in the gastro-intestinal diseases of piglets suckling period by intramuscular injection at a dose of 1.5-2.0 ml, 3 times with an interval of 3-4 days.

Literature

1. Shulga N. N. Increasing the resistance of piglets in the early postnatal period: author. Diss. on saisc. academic step. Kida. wet. Sciences. - Yakutsk, 1997. - 17 S.

2. Smirnov, P. N. , The slip Century. P. and other Pathogenic and immunological value allogeneic serum swiniarski, 1982. - S. 94-100.

3. Goreglyad H. S., Ispenkov A. E. Results and prospects of the study of heterogeneous blood //veterinary medicine. - 1976, 5, S. 88-90.

4. Levitin S. I. Application of the piglets and calves tarirovannoj blood horses //veterinary medicine. - 1975. - 2. - S. 98-99.

5. Antipov, C. A., A. Shakhov, Forest C. I., Efremov Century. And. Prevention and therapy for gastrointestinal diseases of pigs. //Veterinary medicine. - 1979. - 4. - S. 49-51.

6. Antipov, C. A., A. Shakhov,, Drugs for gastrointestinal diseases in piglets and calves //Agriculture abroad. - 1979. - 4. - S. 49-53.

7. Molokanov C. A., hyperimmune Serum antihistamine for the prevention and treatment of inflammatory diseases of the hooves of cattle THAT 3188-001-00493563-00. Approved by the Main veterinary Department Ministry of agriculture of the Russian Federation on may 23, 2000

8. Brewer L. M. Age-related immune deficiencies and their prevention in healthy and patients with dyspepsia piglets. Abstract of Diss. for obtaining the academic step. the candidate's response. Sciences. Vitebsk, 1984, 25 C.

Treatment of immune deficiency and treatment of diseases of the gastrointestinal tract of piglets suckling period, including the introduction in the animal organism, antimicrobial, antihistamines the th drug use antihistamines the serum titer of antibodies to histamine 1: 256, the introduction of which carry intramuscularly in the dose of 1.5-2.0 ml on the head once a day, three times with an interval of 3-4 days.

 

Same patents:
The invention relates to medicine, namely to immunology, and concerns the increase of non-specific anti-infective resistanceat body children

The invention relates to acylaminocinnamic derivative of the formula (I), where R denotes phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, R1is hydrogen, alkyl, R2is hydrogen, alkyl or phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, R3is phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, or represents naphthyl, lH-indol-3-yl or 1-alcheringa-3-yl, R4' and R4"is hydrogen, alkyl, and one of the radicals R4' and R4"is hydrogen, and R5- cycloalkyl, D-azacycloheptan-2-he-3-yl or L-azacycloheptan-2-he-3-yl, or its salt

The invention relates to the preparation, for example, in the form of capsules, soft coated, containing as active ingredient cyclosporine
The invention relates to medicine, in particular to immunology, and related to the increased resistance of the organism

The invention relates to new substituted piperidine-2,6-diones of the formula (I)

where Z is-C(R1R2)-CH2or-C(R1)=CH-; R1- phthalimid, when Z is-C(R1R2)-CH2- or one - or twofold substituted by hydroxy, methoxy or amino groups phtalimide radical when Z represents-C(R1)=CH-, R2is hydrogen or C1-6alkyl group; R3is hydrogen, C1-6an alkyl group or aromatic ring system; R4- C1-6alkyl or aromatic ring

The invention relates to new substituted piperidine-2,6-diones of the formula (I)

where Z is-C(R1R2)-CH2or-C(R1)=CH-; R1- phthalimid, when Z is-C(R1R2)-CH2- or one - or twofold substituted by hydroxy, methoxy or amino groups phtalimide radical when Z represents-C(R1)=CH-, R2is hydrogen or C1-6alkyl group; R3is hydrogen, C1-6an alkyl group or aromatic ring system; R4- C1-6alkyl or aromatic ring

Anti-allergic drug // 2184544
The invention relates to the field of medicine and relates to a drug for treatment of allergic diseases

The invention relates to pharmacology and medicine, in particular to the preparation of solid dosage forms of the drug rapamycin, which includes a core and a sugar coating

The invention relates to purine derivative of L-nucleoside of the formula (I), where R1, R2', R3' and R4- N; R2, R3and R5- HE; Z1- N; Z2selected from N and CH; Z3- NR-, -C(R)2, -S-, where R, same or different, selected from H, Br, NH2, alkyl and alkenyl; Z4selected from C=O, -NR-, -C(R)2- where R, same or different, selected from H and Br; Z5Is N; X is selected from H, HE, SH, -SNH2, -S(O)NH2, -S(O)2NH2Y from H and NH2; W is O, and Y represents NH2then Z3is not a-S-
The invention relates to medicine, namely to the gynecologist? and can be used to stimulate superovulation in IVF

The invention relates to pharmaceutical industry

The invention relates to pharmaceutical industry

The invention relates to medicine and can be used for the treatment of infectious diseases

The invention relates to medicine and relates to a medicinal product for the prevention and treatment of urogenital infections for local use
The invention relates to medicine, in particular to therapy, may be used for the treatment of chronic pharyngitis against the background of a dysbacteriosis of intestines

The invention relates to medicine, in particular to the experimental Hepatology, and for regenerative therapy in liver pathology

The invention relates to acylaminocinnamic derivative of the formula (I), where R denotes phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, R1is hydrogen, alkyl, R2is hydrogen, alkyl or phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, R3is phenyl which is not substituted or may be substituted with halogen, alkyl, trifluoromethyl, hydroxy and alkoxygroup, or represents naphthyl, lH-indol-3-yl or 1-alcheringa-3-yl, R4' and R4"is hydrogen, alkyl, and one of the radicals R4' and R4"is hydrogen, and R5- cycloalkyl, D-azacycloheptan-2-he-3-yl or L-azacycloheptan-2-he-3-yl, or its salt

The invention relates to new compounds of the formula (I)

< / BR>
where AG represents a radical selected from formulas (a) and (b) below:

< / BR>
R1represents a halogen atom, -CH3CH2OR SIG7, -OR SIG7, СОR8, R2and R3taken together form a 5 - or 6-membered ring, R4and R5represent H, a halogen atom, a C1-C10-alkyl, R7represents H, R8represents H orX represents the radical-Y-C-, r' and r" is H, C1-C10alkyl, phenyl, Y represents S(O)nor SE, n = 0, 1, or 2, and salts of compounds of formula (I)

The invention relates to new compounds of the formula (I)

< / BR>
where AG represents a radical selected from formulas (a) and (b) below:

< / BR>
R1represents a halogen atom, -CH3CH2OR SIG7, -OR SIG7, СОR8, R2and R3taken together form a 5 - or 6-membered ring, R4and R5represent H, a halogen atom, a C1-C10-alkyl, R7represents H, R8represents H orX represents the radical-Y-C-, r' and r" is H, C1-C10alkyl, phenyl, Y represents S(O)nor SE, n = 0, 1, or 2, and salts of compounds of formula (I)
Up!